Hospital
Providence Health & Services Washington
Providence Health & Services Washington was paid $40.00M by Medicaid between Jan 2018 and Dec 2024, across 419 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH & SERVICES WASHINGTON
OLYMPIA, WA 98506
OLYMPIA, WA 98506
33aNPI1346250594assigned 08/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$40.00M
24GClaims1,450,611
24DCodes billed419
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#17 of 49
Median peer was paid$20.06M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 220,121 | $6.51M | |
| 2019 | 222,601 | $6.38M | |
| 2020 | 218,035 | $5.95M | |
| 2021 | 251,518 | $6.11M | |
| 2022 | 216,723 | $5.57M | |
| 2023 | 183,012 | $4.98M | |
| 2024incomplete | 138,601 | $4.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 38,805 | 36,270 | $4.13M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.9% | 13,494 | 11,445 | $3.97M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.2% | 39,088 | 36,342 | $3.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.6% | 38,658 | 35,637 | $3.46M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 9,078 | 8,746 | $1.57M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 9,659 | 9,230 | $1.16M |
| 59025 | Fetal non-stress test | 2.8% | 7,129 | 5,008 | $1.10M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.3% | 620 | 619 | $913K |
| 96165 | 2.3% | 4,756 | 1,338 | $906K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.2% | 23,130 | 11,907 | $883K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 7,491 | 5,844 | $850K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 3,735 | 3,695 | $848K |
407 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 11,743 | $739K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 4,047 | $690K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 2,772 | $657K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 3,760 | $599K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 7,210 | $592K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 18,411 | $561K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.4% | 1,401 | $559K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 4,023 | $504K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 4,682 | $495K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.2% | 310 | $493K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 5,991 | $467K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.2% | 5,019 | $460K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.1% | 14,923 | $430K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.0% | 18,522 | $417K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 19,309 | $397K |
| 76830 | Ultrasound, transvaginal | <1% | 3,695 | $311K |
| G0378 | Hospital observation service, per hour | <1% | 17,738 | $304K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,656 | $296K |
| 93971 | <1% | 2,934 | $275K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,328 | $272K |
| 96164 | <1% | 4,758 | $255K | |
| 80053 | Comprehensive metabolic panel | <1% | 49,973 | $240K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,070 | $221K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,071 | $196K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 3,457 | $185K |
| 76801 | <1% | 2,960 | $172K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,083 | $172K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 36,626 | $164K |
| 93017 | <1% | 1,734 | $152K | |
| 93458 | <1% | 194 | $151K | |
| 12001 | <1% | 666 | $147K | |
| 70498 | <1% | 1,364 | $145K | |
| 76770 | <1% | 1,545 | $141K | |
| 97162 | <1% | 3,417 | $138K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 314 | $132K |
| 76937 | <1% | 3,653 | $128K | |
| 97161 | <1% | 2,755 | $119K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 534 | $106K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,245 | $96K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 458 | $96K |
| 70496 | <1% | 1,023 | $88K | |
| 84484 | <1% | 18,285 | $87K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 508 | $84K |
| 36415 | Collection of venous blood by venipuncture | <1% | 43,582 | $75K |
| 36430 | <1% | 766 | $74K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,490 | $73K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,042 | $72K |
| 76870 | <1% | 776 | $70K | |
| 12011 | <1% | 288 | $67K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,230 | $67K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 306 | $65K |
| 10061 | <1% | 297 | $65K | |
| H0036 | Community psychiatric support and treatment, per 15 minutes | <1% | 890 | $65K |
| 71250 | <1% | 1,201 | $62K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 73,218 | $60K |
| 47563 | <1% | 25 | $58K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 856 | $57K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 501 | $57K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,842 | $54K |
| 73610 | <1% | 3,076 | $53K | |
| 97166 | <1% | 1,260 | $52K | |
| 97113 | <1% | 1,263 | $51K | |
| 73630 | <1% | 3,181 | $51K | |
| 72100 | <1% | 3,030 | $50K | |
| 10060 | <1% | 217 | $47K | |
| 87510 | <1% | 4,453 | $46K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,190 | $46K |
| 73130 | <1% | 2,890 | $44K | |
| 92523 | <1% | 380 | $44K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 343 | $44K |
| 73030 | <1% | 3,053 | $42K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 422 | $42K |
| 90715 | <1% | 2,156 | $42K | |
| 87040 | <1% | 6,441 | $41K | |
| 76536 | <1% | 466 | $40K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,936 | $40K |
| 95816 | <1% | 254 | $37K | |
| 84145 | <1% | 4,055 | $37K | |
| 80061 | Lipid panel | <1% | 5,070 | $36K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,299 | $36K |
| 74018 | <1% | 1,879 | $35K | |
| 87400 | <1% | 2,371 | $34K | |
| 73110 | <1% | 1,972 | $34K | |
| 12002 | <1% | 193 | $34K | |
| 73562 | <1% | 984 | $34K | |
| 47562 | <1% | 13 | $33K | |
| 93970 | <1% | 352 | $32K | |
| 97165 | <1% | 804 | $32K | |
| 87660 | <1% | 4,452 | $31K | |
| 92526 | <1% | 660 | $28K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,036 | $27K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,224 | $27K |
| 73140 | <1% | 1,257 | $25K | |
| 73560 | <1% | 2,549 | $25K | |
| 72040 | <1% | 1,494 | $25K | |
| 83605 | <1% | 4,804 | $24K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,356 | $23K |
| 86780 | <1% | 2,034 | $23K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,699 | $23K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 379 | $22K |
| 85379 | <1% | 4,289 | $22K | |
| 73502 | <1% | 1,665 | $22K | |
| 87486 | <1% | 1,699 | $22K | |
| 70470 | <1% | 251 | $21K | |
| 87631 | <1% | 389 | $21K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,500 | $21K |
| 42830 | <1% | 14 | $21K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 93 | $20K |
| 87480 | <1% | 4,452 | $19K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,889 | $19K |
| H2015 | Community support for mental illness or disability, per 15 minutes | <1% | 234 | $19K |
| 83880 | <1% | 3,995 | $19K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 273 | $19K |
| 85027 | <1% | 12,615 | $19K | |
| 95811 | <1% | 50 | $19K | |
| 87641 | <1% | 1,671 | $18K | |
| 97116 | <1% | 1,441 | $18K | |
| 86803 | <1% | 2,306 | $17K | |
| 87581 | <1% | 1,699 | $16K | |
| 82607 | <1% | 1,721 | $15K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 64 | $15K |
| 70486 | <1% | 686 | $15K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 68 | $15K |
| 76882 | <1% | 199 | $14K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,781 | $14K |
| 84439 | <1% | 3,361 | $14K | |
| 84702 | <1% | 3,948 | $14K | |
| 52356 | <1% | 12 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,752 | $13K |
| 96367 | <1% | 413 | $13K | |
| 84403 | <1% | 730 | $12K | |
| 70491 | <1% | 104 | $12K | |
| 83498 | <1% | 473 | $11K | |
| 94726 | <1% | 394 | $11K | |
| 97763 | <1% | 45 | $11K | |
| 86140 | <1% | 3,644 | $10K | |
| 81001 | <1% | 27,705 | $10K | |
| 80050 | General health panel | <1% | 1,436 | $10K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 884 | $10K |
| 29125 | <1% | 41 | $9K | |
| 85651 | <1% | 2,812 | $9K | |
| 83735 | <1% | 6,881 | $9K | |
| 74174 | <1% | 45 | $8K | |
| 87186 | <1% | 4,014 | $8K | |
| 84112 | <1% | 991 | $8K | |
| 83690 | <1% | 16,012 | $8K | |
| 87420 | <1% | 357 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 978 | $8K |
| 88307 | <1% | 448 | $7K | |
| 80076 | <1% | 2,074 | $7K | |
| 86850 | <1% | 4,737 | $7K | |
| 94729 | <1% | 420 | $7K | |
| 82247 | <1% | 1,031 | $7K | |
| 73590 | <1% | 957 | $7K | |
| 87340 | <1% | 2,082 | $7K | |
| 87070 | <1% | 3,933 | $7K | |
| 81025 | <1% | 14,243 | $7K | |
| 74019 | <1% | 321 | $7K | |
| 86901 | <1% | 6,042 | $7K | |
| 82570 | <1% | 1,738 | $6K | |
| 82962 | <1% | 22,226 | $6K | |
| 97163 | <1% | 166 | $6K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 181 | $6K |
| 73090 | <1% | 619 | $6K | |
| 80143 | <1% | 565 | $6K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 68 | $6K |
| 83020 | <1% | 361 | $6K | |
| 84466 | <1% | 996 | $6K | |
| 85610 | <1% | 19,333 | $6K | |
| 84437 | <1% | 361 | $5K | |
| H0023 | Behavioral health outreach service (planned approach to reach a targeted population) | <1% | 34 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,766 | $5K |
| 85055 | <1% | 1,638 | $5K | |
| 72070 | <1% | 274 | $5K | |
| 87077 | <1% | 3,745 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,486 | $4K |
| H0001 | Alcohol and/or drug assessment | <1% | 31 | $4K |
| 87653 | <1% | 286 | $4K | |
| 82728 | <1% | 1,079 | $4K | |
| 85014 | <1% | 2,104 | $4K | |
| 82746 | <1% | 782 | $4K | |
| 86900 | <1% | 6,036 | $4K | |
| 80179 | <1% | 1,693 | $4K | |
| 87505 | <1% | 254 | $4K | |
| 84030 | <1% | 362 | $4K | |
| 97760 | <1% | 170 | $4K | |
| 83540 | <1% | 1,190 | $4K | |
| A9270 | Non-covered item or service | <1% | 23,068 | $3K |
| 73070 | <1% | 528 | $3K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 95 | $3K |
| 87205 | <1% | 3,767 | $3K | |
| 86706 | <1% | 830 | $3K | |
| 96415 | <1% | 14 | $3K | |
| 82043 | <1% | 1,036 | $3K | |
| 93880 | <1% | 61 | $3K | |
| 81003 | <1% | 6,098 | $3K | |
| 86480 | <1% | 244 | $3K | |
| 72170 | <1% | 656 | $3K | |
| 82248 | <1% | 333 | $3K | |
| 92610 | <1% | 91 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 462 | $2K |
| 86923 | <1% | 222 | $2K | |
| 71101 | <1% | 120 | $2K | |
| 82550 | <1% | 1,343 | $2K | |
| 86704 | <1% | 614 | $2K | |
| 87147 | <1% | 1,543 | $2K | |
| 82565 | <1% | 2,962 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,087 | $2K |
| 84703 | <1% | 5,000 | $2K | |
| J3490 | Unclassified drugs | <1% | 2,678 | $2K |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 381 | $2K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,985 | $2K |
| 84100 | <1% | 1,741 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 17 | $2K |
| 87081 | <1% | 959 | $2K | |
| 86762 | <1% | 541 | $2K | |
| 83655 | <1% | 105 | $2K | |
| 85018 | <1% | 1,799 | $2K | |
| 86038 | <1% | 305 | $2K | |
| 88185 | <1% | 91 | $2K | |
| 93922 | <1% | 41 | $2K | |
| 84480 | <1% | 249 | $2K | |
| C1776 | Joint device (implantable) | <1% | 194 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,473 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,113 | $1K |
| 73660 | <1% | 69 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 19,379 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,778 | $1K |
| 72141 | <1% | 12 | $1K | |
| 85652 | <1% | 782 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 26 | $1K |
| 87640 | <1% | 459 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,860 | $1K |
| 94060 | <1% | 30 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,775 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15,721 | $1K |
| 86787 | <1% | 330 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,395 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 20,069 | $1K |
| 96376 | <1% | 5,050 | $1K | |
| 74230 | <1% | 12 | $1K | |
| 84146 | <1% | 71 | $1K | |
| 89051 | <1% | 478 | $1K | |
| 82950 | <1% | 292 | $1K | |
| 82077 | <1% | 1,562 | $971.36 | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,528 | $970.40 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 15,458 | $907.95 |
| 87088 | <1% | 229 | $874.80 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 13 | $861.66 |
| 87075 | <1% | 794 | $848.68 | |
| 99152 | <1% | 2,200 | $821.01 | |
| 92650 | <1% | 24 | $802.08 | |
| 97164 | <1% | 45 | $768.20 | |
| 80164 | <1% | 81 | $670.27 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 502 | $645.13 |
| 85730 | <1% | 2,371 | $621.18 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,236 | $620.41 |
| 86376 | <1% | 41 | $611.01 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,725 | $543.17 |
| 36592 | <1% | 250 | $538.81 | |
| 77012 | <1% | 12 | $520.02 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,467 | $494.46 |
| 87210 | <1% | 647 | $492.76 | |
| 73060 | <1% | 40 | $483.38 | |
| 88342 | <1% | 726 | $481.32 | |
| 80177 | <1% | 49 | $476.63 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,773 | $458.54 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,506 | $455.42 |
| 80178 | <1% | 42 | $446.13 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,913 | $439.26 |
| 36591 | <1% | 813 | $419.88 | |
| C1769 | Guide wire | <1% | 2,849 | $418.69 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 18,213 | $413.75 |
| 84156 | <1% | 243 | $399.61 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,088 | $395.24 |
| 97542 | <1% | 12 | $394.76 | |
| 88304 | <1% | 1,034 | $392.82 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,126 | $367.27 |
| 97130 | <1% | 20 | $355.30 | |
| 82105 | <1% | 29 | $347.82 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,574 | $346.67 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 42 | $338.50 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,602 | $328.65 |
| 86592 | <1% | 82 | $323.63 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,885 | $302.56 |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,976 | $295.22 |
| 84132 | <1% | 917 | $286.95 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,742 | $271.79 |
| J1815 | Injection, insulin, per 5 units | <1% | 5,463 | $271.59 |
| 82677 | <1% | 14 | $268.78 | |
| 82805 | <1% | 465 | $237.22 | |
| 94010 | <1% | 12 | $237.10 | |
| 84425 | <1% | 30 | $234.33 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,405 | $231.06 |
| 83516 | <1% | 50 | $230.47 | |
| 88108 | <1% | 232 | $221.78 | |
| 97129 | <1% | 22 | $216.31 | |
| 87493 | <1% | 77 | $196.99 | |
| 83921 | <1% | 29 | $191.60 | |
| 84550 | <1% | 72 | $184.22 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,190 | $176.48 |
| 87116 | <1% | 94 | $170.69 | |
| 82731 | <1% | 16 | $170.12 | |
| 36410 | <1% | 136 | $151.99 | |
| 82670 | <1% | 12 | $148.64 | |
| 82360 | <1% | 25 | $132.11 | |
| 88341 | <1% | 279 | $129.34 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 483 | $129.28 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,143 | $118.55 |
| 90686 | <1% | 14 | $114.22 | |
| 88184 | <1% | 87 | $104.53 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 349 | $103.59 |
| 73552 | <1% | 12 | $99.43 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,782 | $94.57 |
| 82140 | <1% | 57 | $91.71 | |
| 84153 | <1% | 12 | $83.81 | |
| 83520 | <1% | 16 | $83.70 | |
| 86430 | <1% | 12 | $79.14 | |
| 82803 | <1% | 117 | $76.42 | |
| 86431 | <1% | 17 | $72.14 | |
| 83001 | <1% | 12 | $65.69 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,476 | $51.21 |
| 82330 | <1% | 331 | $51.05 | |
| 83550 | <1% | 14 | $50.43 | |
| 86705 | <1% | 12 | $45.87 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 479 | $45.80 |
| 86336 | <1% | 14 | $45.39 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,642 | $43.92 |
| 86708 | <1% | 14 | $38.77 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,483 | $37.20 |
| 87176 | <1% | 12 | $35.87 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,064 | $29.98 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,810 | $27.43 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 963 | $27.13 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,810 | $26.44 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 990 | $25.22 |
| 36600 | <1% | 86 | $24.04 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,677 | $23.12 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,189 | $22.03 |
| 82010 | <1% | 208 | $21.88 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 343 | $21.37 |
| J7999 | Compounded drug, not otherwise classified | <1% | 125 | $20.37 |
| 87206 | <1% | 130 | $15.50 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,885 | $14.39 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,787 | $13.45 |
| 88313 | <1% | 14 | $12.29 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,686 | $12.19 |
| 88112 | <1% | 177 | $11.05 | |
| 82945 | <1% | 13 | $8.23 | |
| 87015 | <1% | 67 | $5.22 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,094 | $5.09 |
| 84157 | <1% | 14 | $4.11 | |
| C1758 | Catheter, ureteral | <1% | 254 | $3.02 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,970 | $2.97 |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 448 | $2.64 |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 148 | $2.17 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,064 | $2.16 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,516 | $1.93 |
| 82947 | <1% | 142 | $1.76 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 169 | $0.20 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 361 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 232 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 40 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 312 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 57 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 562 | $0.00 |
| 82435 | 0% | 160 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 244 | $0.00 |
| 31623 | 0% | 25 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 140 | $0.00 |
| 94761 | 0% | 851 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 41 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 588 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 30 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 104 | $0.00 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 0% | 126 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 17 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 12 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 50 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 18 | $0.00 |
| 0099U | 0% | 18 | $0.00 | |
| 74022 | 0% | 12 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 661 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 411 | $0.00 |
| 85347 | 0% | 82 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 157 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 199 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 43 | $0.00 |
| 84295 | 0% | 177 | $0.00 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 131 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 449 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 260 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 0% | 27 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 195 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 288 | $0.00 |
| J2359 | Injection, olanzapine, 0.5 mg | 0% | 133 | $0.00 |
| 51702 | 0% | 12 | $0.00 | |
| 92611 | 0% | 12 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 13 | $0.00 |
| 31624 | 0% | 28 | $0.00 | |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 41 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 50 | $0.00 |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 0% | 28 | $0.00 |
| 88173 | 0% | 23 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 12 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 221 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY FOR ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.